Recently, Doctor Chen Weiming of the School of Pharmacy (SN) signed a cooperation agreement with Shanghai Haoyuan Bio-Medicine Technology Co., Ltd. so as to jointly research and develop drug molecules. This cooperation lasts for 2 years. The company will sponsor 500,000 Yuan for development. The first 90,000 Yuan for development fund has been transferred into GMU’S account. And the project is being conducted. This is the scientific research project enjoying the largest amount of financial support from the cooperation between GMU and enterprises up to now. What’s more, it is an important achievement of GMU to serve the development of biomedical industry and vigorously promote the production-university-research cooperation.
  Located in Zhangjiang Bio-Medicine Base and specializing in the research and development of inhibitors for pharmaceutical intermediates and signal transduction, Shanghai Haoyuan Bio-Medicine Technology Co., Ltd. is an innovative bio-medicine company with independent R&D capability, high-end synthesis level and proprietary IPR.
    The head office is a high-tech enterprise established in September 2006. The company is mainly engaged in the research and development of related compounds in the development of new drugs and the featured pharmaceutical apis and advanced intermediates, etc. Meanwhile, it also provides domestic and foreign pharmaceutical enterprises with commissioned development, license application and production technology improvement services for new drugs and generic drugs. The company services cover the development and research for chiral drug, Vitamin D derivative and active molecule library.